Helsinn seeks SCOTUS review of patent case
05-03-2018
Federal Circuit reverses district court’s on-sale bar ruling
02-05-2017
renaschild / iStockphoto.com
The US Supreme Court has agreed to hear a dispute over whether confidential sales of an invention can trigger the on-sale bar and invalidate a patent under the America Invents Act (AIA).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Helsinn Healthcare, Teva Pharmaceuticals, cancer, cancer treatment, US Supreme Court, Eisai, chemotherapy, Federal Circuit
